MRNS - Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday? | Benzinga
Monday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients, with topline results expected in the summer of 2024.
The results will be used to determine whether to continue the development of IV ganaxolone. Marinus remains blinded to the RAISE trial data.
“While we are disappointed that RAISE did not meet the early stopping criteria, we will only ...